DeepMed Research

Hydrochlorothiazide

Generic Name: Hydrochlorothiazide

Brand Names: Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈ClN_₃O_₄S_₂

CAS Number: 58-93-5

Unique Ingredient Identifier: 0J48LPH2TH

Background: Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication: Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions: Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke

Clinical Trials

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

Phase 4

Withdrawn

Conditions: Hypertension
Diabetes Mellitus, Type 2

Interventions: Drug: Hydrochlorothiazide 12.5mg
Drug: Ertugliflozin
Device: Microneurography
Other: SKNA recordings
Other: Static Handgrip
Other: Post-handgrip forearm vascular occlusion
Other: Testing of the Arterial Baroreflex Function

First Posted Date: 2018-08-21

Last Posted Date: 2020-01-14

Lead Sponsor: Cedars-Sinai Medical Center

Registration Number: NCT03640221

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting

Conditions: Breastfed Infants of Mothers on Select DOI
Lactating Women on Select DOI

First Posted Date: 2018-04-27

Last Posted Date: 2024-12-17

Lead Sponsor: Duke University

Target Recruit Count: 1600

Registration Number: NCT03511118

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Loma Linda University Health, Loma Linda, California, United States

and more 19 locations

Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide

Recruiting

Conditions: Obesity, Morbid

First Posted Date: 2018-03-26

Last Posted Date: 2023-04-13

Lead Sponsor: Norwegian University of Science and Technology

Target Recruit Count: 12

Registration Number: NCT03476551

Locations: 🇳🇴
St. Olavs University Hospital, Trondheim, Norway

N-of-1 Trials In Children With Hypertension

Phase 4

Completed

Conditions: Pediatric Hypertension

Interventions: Other: Usual care
Other: NICHE method
Drug: Amlodipine
Drug: Lisinopril
Drug: Hydrochlorothiazide
Drug: Losartan

First Posted Date: 2018-03-09

Last Posted Date: 2022-09-09

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 49

Registration Number: NCT03461003

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Phase 4

Withdrawn

Conditions: Type 2 Diabetes Mellitus (T2DM)

Interventions: Drug: Dapagliflozin (Forxiga®)
Drug: Placebo matching Dapagliflozin
Drug: Hydrochlorothiazide 25 mg

First Posted Date: 2018-02-06

Last Posted Date: 2021-12-15

Lead Sponsor: University Hospital Tuebingen

Registration Number: NCT03423355

Locations: 🇩🇪
University Hospital Tuebingen, Otfried-Mueller Str. 10, Tuebingen, Germany

Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects

Phase 1

Completed

Conditions: Drug-Drug Interaction

Interventions: Drug: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide

First Posted Date: 2018-01-04

Last Posted Date: 2018-08-10

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 36

Registration Number: NCT03390465

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sotagliflozin (SAR439954)
Drug: Hydrochlorothiazide

First Posted Date: 2018-01-02

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT03387657

Locations: 🇺🇸
Investigational Site Number 8400001, Dallas, Texas, United States

Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide

Phase 3

Recruiting

Conditions: Pre-Eclampsia
Gestational Hypertension
Superimposed Pre-Eclampsia
Hypertension, Pregnancy-Induced
Postpartum Pregnancy-Induced Hypertension
Postpartum Preeclampsia

Interventions: Drug: Hydrochlorothiazide 50mg Tablet
Drug: Placebo Tablet

First Posted Date: 2017-10-02

Last Posted Date: 2023-12-05

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 612

Registration Number: NCT03298802

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸
St. David's North Austin Medical Center, Austin, Texas, United States

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

Phase 2

Active, not recruiting

Conditions: Sedentary Lifestyle
Aging
Hypertension

Interventions: Behavioral: Aerobic exercise
Drug: Perindopril
Drug: Losartan
Drug: HCTZ

First Posted Date: 2017-09-28

Last Posted Date: 2024-05-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 213

Registration Number: NCT03295734

Locations: 🇺🇸
UAB Center for Exercise Medicine, Birmingham, Alabama, United States
🇺🇸
Translational Research Institute, Orlando, Florida, United States

A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension

Phase 4

Completed

Conditions: Hypertension
Pharmacogenetics

Interventions: Drug: Placebo
Drug: Amlodipine
Drug: Losartan
Drug: Bisoprolol
Drug: Hydrochlorothiazide

First Posted Date: 2017-09-08

Last Posted Date: 2017-09-11

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 233

Registration Number: NCT03276598

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy